TNF and colorectal carcinoma: The pooled results demonstrated a statistically significant reduction in TNF-α levels in CRC patients receiving ω-3 PUFA supplementation compared to the placebo group [MD = −1.11, 95%CI (−2.07, −0.15), Z = 2.26, p = 0.02 < 0.05].